Fig. 1: Correlative study endpoints analyses workflow. | Nature Communications

Fig. 1: Correlative study endpoints analyses workflow.

From: The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Fig. 1

a Workflow to detect molecular correlates to CHK1i treatment. Pre-treatment fresh core biopsies were collected from patients with safely biopsiable diseases enrolled in the clinical trial (NCT02203513). Genomic (BROCA GOv.1 panel and WES) and transcriptomic analyses were performed to identify the molecular characteristics between patients with clinical benefit (PFS ≥ 6 months) and no clinical benefit (PFS < 6 months). b Workflow to detect pharmacodynamic biomarkers reflecting CHK1i therapy. Paired blood samples were collected at baseline and at C1D15 to evaluate dynamic changes in EpCAM+ CTCs and immune cell subsets in patients with and without clinical benefit. The figure was created with BioRender.com. Abbreviations: BRCAwt BRCA wild-type, C1D15 Cycle 1 Day 15, CHK1i CHK1 inhibitor, CTCs circulating tumor cells, DNAseq DNA sequencing, EpCAM epithelial cell adhesion molecules, GSEA gene set enrichment analysis, PBMC peripheral blood mononuclear cells, PR-HGSOC platinum-resistant high-grade serous ovarian cancer, WES whole exome sequencing.

Back to article page